Bank Julius Baer & Co. Ltd Zurich Takes $267,000 Position in ResMed Inc. (NYSE:RMD)

Bank Julius Baer & Co. Ltd Zurich acquired a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,060 shares of the medical equipment provider's stock, valued at approximately $267,000.

Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in ResMed by 10.9% in the third quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider's stock valued at $939,114,000 after buying an additional 380,383 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of ResMed by 60.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock worth $152,973,000 after acquiring an additional 250,746 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in ResMed by 726.3% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider's stock worth $69,281,000 after purchasing an additional 249,454 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in ResMed in the fourth quarter valued at approximately $50,364,000. Finally, Nordea Investment Management AB increased its stake in ResMed by 92.7% in the fourth quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider's stock valued at $103,214,000 after purchasing an additional 215,561 shares during the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

Several equities research analysts recently commented on RMD shares. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. StockNews.com downgraded ResMed from a "buy" rating to a "hold" rating in a report on Friday, March 7th. UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a research note on Thursday, January 16th. They set a "buy" rating for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, ResMed presently has a consensus rating of "Moderate Buy" and an average target price of $243.82.

ResMed Price Performance

NYSE:RMD traded down $3.82 during trading hours on Wednesday, reaching $221.98. 303,849 shares of the company traded hands, compared to its average volume of 970,235. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The firm's 50-day moving average is $236.80 and its 200-day moving average is $240.13. The stock has a market cap of $32.60 billion, a P/E ratio of 26.21, a P/E/G ratio of 1.53 and a beta of 0.74. ResMed Inc. has a 1-year low of $172.19 and a 1-year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Equities research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Thursday, February 13th. ResMed's payout ratio is 25.03%.

Insider Activity

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $229.20, for a total transaction of $1,835,662.80. Following the transaction, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $104,394,182.40. The trade was a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kaushik Ghoshal sold 9,113 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the completion of the transaction, the insider now directly owns 9,725 shares in the company, valued at approximately $2,289,265. This represents a 48.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,940 shares of company stock valued at $9,164,385 in the last 90 days. 0.71% of the stock is currently owned by insiders.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.